Tolterodine

Introduction Overview

Generic Name

tolterodine

Brand Name

Detrol, Detrol LA

Dosage Form

oral capsule, extended release (2 mg; 4 mg), oral tablet (1 mg; 2 mg)

Drug Class

Urinary antispasmodics

Pharmacokinetics

Absorption:
Tolterodine is well absorbed from the gastrointestinal tract upon oral administration, with a bioavailability of approximately 77%, attributed in part to significant first-pass hepatic metabolism. Peak plasma concentrations of immediate release formulations occur typically within 1 hour, whereas extended release formulations show a slower absorption with peak plasma levels at approximately 6 hours, providing prolonged drug action. Food intake does not significantly affect the extent of absorption, although it may delay the absorption rate somewhat.

Distribution:
Tolterodine is widely distributed throughout the body with an apparent volume of distribution between 113 to 140 liters, indicative of extensive tissue penetration. It is approximately 96% bound to plasma proteins, primarily albumin. The drug crosses the blood-brain barrier to a limited extent, which may partially account for observed central nervous system side effects such as dizziness or confusion. Its distribution into the bladder detrusor muscle targets the therapeutic site effectively.

Metabolism:
Tolterodine undergoes extensive hepatic metabolism primarily via cytochrome P450 enzyme CYP2D6 and to a lesser extent CYP3A4. Two major metabolites are produced: 5-hydroxymethyl tolterodine, which retains antimuscarinic activity similar to the parent compound, contributing to efficacy, and the 5-carboxy metabolite, which is inactive. Genetic polymorphisms in CYP2D6 influence the metabolism rate, yielding extensive and poor metabolizer phenotypes that affect plasma drug concentrations and potential side effects.

Elimination:
The drug and its metabolites are primarily eliminated via renal excretion (approximately 70-80%) and to a lesser extent via feces. The elimination half-life of tolterodine is about 2 to 4 hours with immediate release formulations and about 6 to 9 hours with extended release capsules, supporting once or twice daily dosing regimens. Clearance may be reduced in patients with hepatic or renal impairment, necessitating dose adjustments. The active metabolite's half-life is longer, contributing to overall drug activity.

Dosage Forms

Available Dosage Forms:
Tolterodine is available as immediate-release oral tablets and extended-release oral capsules. The specific formulations include:
- Oral tablet: 1 mg, 2 mg
- Extended release oral capsule: 2 mg, 4 mg

Dosages for Adults and Adolescents:
For adults with overactive bladder symptoms (urinary incontinence, urgency, frequency), dosing recommendations are:
- Immediate-release tablets: Initial dose 2 mg orally twice daily; maintenance doses range from 1 to 2 mg orally twice daily based on clinical response and tolerability.
- Extended-release capsules: Initial dose 4 mg orally once daily; maintenance dose can be adjusted between 2 to 4 mg once daily depending on patient response and side effects.

Specific Patient Populations:
- Hepatic impairment: Patients with moderate hepatic impairment should receive reduced doses, particularly avoiding extended release formulations, due to decreased metabolism.
- Renal impairment: Dose adjustments may be required for patients with renal dysfunction since clearance of metabolites is reduced.
- Elderly: No specific adjustments, but caution is advised as elderly may be more sensitive to anticholinergic effects.
- Pediatric: Safety and efficacy have not been established in pediatric populations.

Clinical guidelines emphasize that extended-release capsules should be swallowed whole and can be taken with or without food. Immediate-release tablets are also administered irrespective of meals.

Mechanism Of Action

Tolterodine is a competitive antagonist of muscarinic receptors, primarily targeting the M2 and M3 subtypes located on the smooth muscle of the urinary bladder detrusor muscle. By inhibiting these receptors, tolterodine suppresses acetylcholine-mediated detrusor muscle contractions that lead to involuntary bladder contractions and symptoms of overactive bladder such as urgency and incontinence.

At the molecular level, tolterodine binds to muscarinic receptors in the bladder, preventing acetylcholine from binding and activating G-protein-coupled receptor signaling pathways responsible for muscle contraction. This blockade reduces bladder muscle spasms and increases bladder capacity, thereby reducing urgency and frequency.

The active metabolite 5-hydroxymethyl tolterodine contributes significantly to the therapeutic effect and shares similar receptor affinity. Tolterodine has relative selectivity for the bladder over salivary glands compared to other antimuscarinics, potentially resulting in a somewhat lower incidence of dry mouth.

Clinically, tolterodine's antimuscarinic action translates to effective management of involuntary bladder contractions without completely abolishing normal bladder function. Compared to other antimuscarinics like oxybutynin, tolterodine may offer a more favorable tolerability profile, although both share similar mechanisms. Research studies including randomized controlled trials have demonstrated tolterodine's efficacy in reducing urinary episodes and improving quality of life in patients with overactive bladder.

Pharmacological Actions

Competitive antagonism of muscarinic receptors M2 and M3 in urinary bladder smooth muscle
Reduction of detrusor smooth muscle contraction leading to decreased urinary urgency and frequency
Increased bladder storage capacity by relaxing bladder muscle tone
Minimal central nervous system penetration reducing CNS side effects relative to some antimuscarinics
Active metabolite 5-hydroxymethyl tolterodine exhibits similar antimuscarinic activity
Inhibition of acetylcholine-mediated parasympathetic stimulation in the bladder
Improves symptoms of urinary incontinence by suppressing involuntary bladder spasms
Exhibits selectivity favoring bladder muscarinic receptors over salivary glands leading to reduced dry mouth incidence
Modulation of bladder sensory afferent pathways contributing to decreased urgency sensation
Extended-release formulations provide prolonged muscarinic blockade maintaining therapeutic plasma concentrations
Metabolized by CYP2D6 enzyme system, resulting in pharmacogenetic variability
Exhibits partial anticholinergic effects systemically with potential impact on heart rate and smooth muscle elsewhere
Reduces nocturia and urinary frequency episodes documented in clinical trials
Mechanism is reversible and dose-dependent allowing titratable clinical response
Relative sparing of nicotinic receptors, focusing action on muscarinic receptor-mediated pathways

Therapeutic Or Clinical Uses

Treatment of overactive bladder syndrome in adults characterized by urinary urgency
Management of urge urinary incontinence associated with detrusor overactivity
Reduction of urinary frequency and nocturia due to overactive bladder
Adjunct therapy to improve quality of life in patients with symptoms of urinary urgency
Alternative to oxybutynin and other antimuscarinics with similar indications
Used in patients intolerant to first-line therapies for urinary bladder muscle hyperactivity
Treatment of symptoms related to idiopathic detrusor overactivity
Management tool to reduce incontinence episodes in neurologic bladder dysfunction in adults
Mitigation of urinary symptoms in older adult population with bladder instability
Pharmacological option to reduce bladder spasms post-pelvic surgeries or irradiation
Off-label use in bladder conditions with parasympathetic overactivity where muscarinic antagonism is beneficial
Potential role in combination therapy regimens to optimize bladder symptom control
Utilized in clinical practice guidelines for bladder muscle spasm-related urinary disorders
Supported by randomized clinical trials demonstrating efficacy and safety profile
Reducing severity and frequency of urgency episodes in patients refractory to conservative measures

Side Or Adverse Effects

Dry mouth, a common anticholinergic side effect due to salivary gland muscarinic blockade
Dizziness and somnolence, possibly related to mild CNS penetration
Constipation caused by decreased gastrointestinal motility
Stomach pain or abdominal discomfort
Headache reported in some patients during therapy
Confusion and hallucinations, particularly in elderly or those with CNS vulnerability
Serious urinary retention or difficulty urinating requiring immediate medical attention
Allergic reactions including hives, swelling of face, lips, tongue, or throat
Potential for constipation leading to bowel obstruction in susceptible individuals
Blurred vision or accommodation disturbances related to antimuscarinic effects on the eye
Tachycardia or palpitations due to systemic anticholinergic activity
Fatigue or weakness occasionally reported
Dry eyes and decreased sweating (anhidrosis) in rare cases
Risk of QT interval prolongation and associated arrhythmias when combined with other culprit drugs
Increased intraocular pressure, worsening glaucoma symptoms if present

Precautions

Use cautiously in patients with impaired bladder emptying or urinary retention
Monitor patients with a history of gastrointestinal obstruction or severe constipation
Use with caution in elderly patients due to increased risk of CNS side effects like confusion
Assess liver and kidney function prior to and during treatment to adjust dosing appropriately
Avoid use in patients with uncontrolled narrow-angle glaucoma
Evaluate QT interval prolongation risk especially in patients with predisposing cardiovascular conditions
Caution in patients with myasthenia gravis as anticholinergics may worsen muscle weakness
Avoid abrupt discontinuation in patients dependent on tolterodine for bladder control
Monitor for anticholinergic toxicity when used concomitantly with other antimuscarinic drugs
Advise patients to avoid activities requiring mental alertness until effects of the drug are known
Use caution during pregnancy and breastfeeding; consult healthcare provider
Regularly assess for signs of allergic reactions during therapy
Monitor for potential drug interactions that may increase drug levels or side effect risk
Dose adjustments suggested in patients with moderate hepatic or severe renal impairment
Educate patients about the importance of adherence to dosing schedules and not doubling doses

Warnings

Risk of serious allergic reactions including anaphylaxis and angioedema
Potential for confusion, hallucinations, and other CNS disturbances especially in elderly
Discontinue tolterodine immediately if severe stomach pain or constipation occurs
Risk of urinary retention, particularly in men with prostatic hypertrophy or bladder outlet obstruction
Not recommended in patients with uncontrolled narrow-angle glaucoma due to risk of increased intraocular pressure
May cause QT interval prolongation, increasing the risk of serious cardiac arrhythmias
Use caution when administered with other drugs known to prolong QT interval
Avoid use in patients with known hypersensitivity to tolterodine or related antimuscarinic drugs
Risk of impaired ability to perform hazardous tasks such as driving until drug effects are known
Use only as prescribed; overdose can cause severe anticholinergic toxicity
Should not be used by patients with gastrointestinal obstruction or severe motility disorders
May worsen symptoms of myasthenia gravis
Use with caution in patients with a history of urinary retention
Risk of exacerbating conditions with autonomic nervous system involvement
Abrupt withdrawal may lead to rebound symptoms of overactive bladder

Contraindication

Hypersensitivity to tolterodine or fesoterodine
Patients with uncontrolled narrow-angle glaucoma
Individuals with urinary retention or significant bladder outflow obstruction
Patients with known gastrointestinal obstruction or severe motility disorders
History of acetylcholine receptor antagonist hypersensitivity reactions
Severe hepatic impairment contraindicates use of extended-release preparations
Known hypersensitivity to any component of the formulation
Conditions where anticholinergic effects may exacerbate disease states such as myasthenia gravis
Presence of toxic megacolon or gastrointestinal paralysis
Children and adolescents due to lack of established safety data
Patients with prolonged QT interval or torsades de pointes history without cardiology clearance
Patients with severe uncontrolled cardiac arrhythmias
Use is not recommended in breastfeeding women without medical supervision
Severe renal impairment requiring dialysis without adjustment may be contraindicated
Patients with acute asthma or other severe obstructive pulmonary disease exacerbations

Drug Interactions

Concomitant use with CYP3A4 inhibitors such as ketoconazole or erythromycin may increase tolterodine plasma levels
CYP2D6 poor metabolizers exhibit increased exposure to tolterodine; caution with CYP2D6 inhibitors like fluoxetine
Combination with drugs that prolong QT interval (e.g., some antiarrhythmics, antipsychotics) increases risk of arrhythmias
Concomitant use with cyclosporine, due to increased tolterodine exposure and toxicity
Interaction with vinblastine which may alter tolterodine metabolism
Additive anticholinergic effects can occur when combined with other antimuscarinic agents or drugs with anticholinergic properties
Co-administration with drugs causing CNS depression (e.g., benzodiazepines, opioids) may exacerbate dizziness or somnolence
Use with caution alongside cholinesterase inhibitors, which may have opposing effects
Potential interaction with other drugs affecting bladder function, such as beta-3 agonists
May reduce the therapeutic efficacy of drugs that depend on parasympathetic stimulation
Concurrent use with alcohol may intensify CNS side effects like dizziness and sedation
Alterations in gastrointestinal motility from other medications may affect tolterodine absorption
P-glycoprotein substrates may interact, but the clinical significance remains under investigation
Possible interactions with herbal supplements such as St. John's Wort affecting CYP enzyme activity
Patient monitoring is advised when initiating or discontinuing interacting medications to avoid adverse events

Preparations Of The Drug

Immediate release oral tablets: 1 mg, 2 mg strength available for twice daily dosing
Extended release oral capsules: 2 mg, 4 mg strength formulated for once daily administration
Film-coated tablets designed for easy swallowing and stability
Capsules designed to be swallowed whole; not to be crushed or chewed to maintain extended-release properties
Commercially available in blister packs or bottles to preserve drug stability and prevent moisture ingress
Formulations manufactured under Good Manufacturing Practices (GMP) adhering to FDA standards
Fortified formulations in some countries with additives to enhance shelf life without affecting pharmacokinetics
Generic versions widely available, ensuring accessibility and cost-effectiveness
Storage recommendation includes room temperature away from moisture, heat, and direct light
Packaging includes child-resistant features to prevent accidental ingestion
Availability in various markets may differ; consultation with healthcare provider advised
Supplemental patient instruction leaflets included to promote correct medication use
Preserved in formulations without lactose or gluten to accommodate dietary restrictions
Dosage forms compatible with concomitant use of other medications in polypharmacy settings
Preparation approved by regulatory agencies such as FDA and EMA with ongoing post-marketing surveillance